Biolegend, 317331, Brilliant Violet 510™ anti-human CD3 Antibody, 25tests

CD3ε is a 20 kD chain of the CD3/T cell receptor (TCR) complex, which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.
25tests
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Mouse
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.Clone OKT3 can block the binding of clones SK7 and UCHT1.4 The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Application References(PubMed link indicates BioLegend citation): Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego. Li B, et al. 2005. Immunology 116:487. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed Alter G, et al. 2008. J. Virol. 82:9668. PubMed Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed Pinto JP, et al. 2010. Immunology. 130:217. PubMed Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed
Product Citations: Wheatley A, et al. 2016. Sci Rep. 6: 26478. PubMed Nguyen THO, et al. 2023. Cell Rep Med. 4:101017. PubMed Zhang W, et al. 2023. Nat Immunol. 24:966. PubMed Swadling L, et al. 2022. Nature. 601:110. PubMed Bjarnadóttir U, et al. 2022. Scand J Immunol. 95:e13116. PubMed Rowntree LC, et al. 2022. Immunity. 55:1299. PubMed McEvoy CM, et al. 2022. Nat Commun. 13:7634. PubMed Xu Q, et al. 2023. Nat Immunol. 24:186. PubMed Touizer E, et al. 2023. iScience. 26:105862. PubMed Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed Leeansyah E, et al. 2015. PLoS Pathog. 11: 1005072. PubMed Ishizaka A, et al. 2016. J Virol. 90: 5665 - 5676. PubMed Andrews SF et al. 2019. Immunity. 51(2):398-410 . PubMed Lamichhane R, et al. 2020. Eur J Immunol. 50:178. PubMed Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed Chiu Y, et al. 2016. Sci Rep. 6:19227. PubMed Abreu C, et al. 2014. PLoS One. 9:97257. PubMed Kimura I, et al. 2022. Cell Rep. 38:110218. PubMed Piepenbrink MS, et al. 2021. Cell Reports Medicine. 2(3):100218. PubMed Sutton HJ, et al. 2021. Cell Reports. 34(6):108684. PubMed Zhou J, et al. 2015. J Immunol. 194:4688. PubMed Petrelli A, et al. 2018. J Clin Invest. 128:4669. PubMed Antonucci L, et al. 2020. Journal of Immunology Research. 3257.929861. PubMed Juno JA, et al. 2020. Nat Med. 26:1428. PubMed Kreutmair S, et al. 2021. Immunity. . PubMed Herter JM, et al. 2022. Strahlenther Onkol. Online ahead of print. PubMed Tan J, et al. 2021. Sci Transl Med. 13: . PubMed Nguyen THO, et al. 2021. Immunity. 54:1066. PubMed Yu C, et al. 2021. Med (N Y). 2:755. PubMed Lu Q, et al. 2021. Immunity. 54(6):1304-1319.e9. PubMed Ehlers L, et al. 2021. The FASEB Journal. 35(7):e21684. PubMed Sordé L, et al. 2017. Immunity, Inflammation, and Disease. 10.1002/iid3.167. PubMed van den Hoogen P, et al. 2020. PLoS One. 14:e0227283. PubMed Port JR, et al. 2020. J Virol. 94:. PubMed Einkauf KB, et al. 2019. J Clin Invest. 129:988. PubMed Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed Jiang C, et al. 2020. Nature. 261:585. PubMed Einkauf KB, et al. 2022. Cell. 185:266. PubMed Wang L, et al. 2021. Science. 373:. PubMed Motozono C, et al. 2021. Cell Host Microbe. . PubMed Gross C, et al. 2016. Proc Natl Acad Sci U S A. 113: 2973 - 2982. PubMed Dacon C, et al. 2022. Cell Host Microbe. Online ahead of print. PubMed Smalley M, et al. 2020. iScience. 23:101229. PubMed Hearps AC, et al. 2017. Front Immunol. 0.840972222. PubMed Cho H, et al. 2021. Sci Transl Med. 13:eabj5413. PubMed Cui J, et al. 2019. Neuro Oncol. 21:1436. PubMed Abd Hamid M et al. 2019. Cancer Immunol Res. 7(8):1293-1306 . PubMed Seydoux E, et al. 2020. Immunity. 53:98. PubMed Sant S, et al. 2020. PLoS Pathog. 16:e1008714. PubMed Burian A, et al. 2016. PLoS One. 11: 0163297. PubMed Aguilar–Briseñ o JA, et al. 2020. Nat Commun. 2.664583333. PubMed Lamichhane R et al. 2019. Cell Rep. 28(12):3061-3076 . PubMed
RRID: AB_2561376 (BioLegend Cat. No. 317331) AB_2561943 (BioLegend Cat. No. 317332)
Structure: Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD
Distribution: Mature T and NK T cells, thymocyte differentiation
Function: Antigen recognition, signal transduction, T cell activation
Ligand/Receptor: Peptide antigen bound to MHC
Cell Type: NKT cells, T cells, Thymocytes, Tregs
Biology Area: Immunology
Molecular Family: CD Molecules
Antigen References: Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego. Beverly P, et al. 1981. Eur. J. Immunol. 11:329. Lanier L, et al. 1986. J. Immunol. 137:2501.
Gene ID: 916
UniProt: View information about CD3 on UniProt.org
Clone: OKT3
Regulatory Status: RUO
Workshop: HCDM listed
Other Names: T3, CD3ε
Isotype: Mouse IgG2a, κ